Company Performance - Personalis reported a quarterly loss of $0.18 per share, better than the Zacks Consensus Estimate of a loss of $0.23, and an improvement from a loss of $0.26 per share a year ago, representing an earnings surprise of 21.74% [1] - The company posted revenues of $20.61 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 18.20%, compared to year-ago revenues of $19.53 million [2] - Over the last four quarters, Personalis has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] Stock Outlook - Personalis shares have declined approximately 26.3% since the beginning of the year, contrasting with the S&P 500's decline of 3.9% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.24 on revenues of $17.49 million, and for the current fiscal year, it is -$0.94 on revenues of $83.99 million [7] Industry Context - The Medical - Generic Drugs industry, to which Personalis belongs, is currently ranked in the top 17% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that the industry outlook can significantly impact stock performance [5][8]

Financial Data and Key Metrics Changes - Company achieved revenues of over $20,600,000 in Q1 2025, representing a 6% increase compared to $19,500,000 in the same period last year [24][9] - Biopharma revenue grew to $13,600,000, a 39% increase from $9,800,000 in Q1 2024 [24][20] - Gross margin improved to 35% from 28.1% year-over-year, primarily due to a favorable customer mix [25][26] - Net loss for Q1 2025 was $15,800,000 compared to $13,000,000 in the prior year [27] Business Line Data and Key Metrics Changes - Clinical diagnostic business had its highest quarterly revenue to date, contributing to overall revenue growth [9] - Molecular tests delivered increased by 52% to 2,184 tests compared to 1,441 in Q4 2024 [10] - The company is tracking to achieve 30% to 40% quarter-over-quarter growth in molecular results [9] Market Data and Key Metrics Changes - The MRD testing market is expected to mature into a $20,000,000,000 market, with Personalis positioned for success [7] - Approximately 40% of MRD positive results are in the ultra-sensitive range, which is a key differentiator [11] Company Strategy and Development Direction - The company is focused on a "win in MRD" strategy, emphasizing customer care and robust experience [12] - Plans to deepen clinical evidence and achieve reimbursement for three indications: breast cancer, lung cancer, and immunotherapy monitoring [12][13] - The company aims to expand its tumor profiling product portfolio to capture additional business from biopharma [21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving reimbursement for at least two indications in 2025 [13] - The company is optimistic about the potential of its colorectal cancer data to drive future revenue [18] - Management highlighted the importance of maintaining a balance between growth and cost management in the absence of reimbursement [42] Other Important Information - Cash and cash equivalents at the end of Q1 2025 were $185,700,000, providing a comfortable runway for growth objectives [9] - The company raised approximately $17,800,000 through common stock sales during the quarter [28] Q&A Session Summary Question: Will the company steer its commercial organization towards breast cancer patients if reimbursement comes through this year? - Management confirmed that efforts are already focused on breast cancer, lung cancer, and immunotherapy monitoring, with plans to accelerate once reimbursement is clear [32][33] Question: What is the retention rate of doctors ordering tests? - Management reported high retention rates, with several hundred physicians now ordering tests, a mix of new and recurring orders [35][36] Question: How does the company view the growth in marketing efforts pre- and post-reimbursement? - Management indicated that they are currently metering growth but could accelerate efforts significantly once reimbursement is achieved [40][41] Question: Can the company provide an update on the Victory study data? - Management expressed satisfaction with the interim results, noting high sensitivity in detecting recurrences in colorectal cancer patients [54][55] Question: What is the commercialization strategy following the MolDXPress filing? - Management reiterated confidence in tracking ahead of schedule for reimbursement approvals and highlighted the potential for catch-up revenue once positive decisions are made [74][75]

Financial Data and Key Metrics Changes - Company achieved revenues of over $20,600,000 in Q1 2025, representing a 6% increase compared to $19,500,000 in the same period last year [24] - Biopharma revenue grew to $13,600,000, a 39% increase from $9,800,000 in Q1 2024 [24][21] - Gross margin improved to 35% from 28.1% year-over-year, primarily due to a favorable customer mix [26] - Net loss for Q1 was $15,800,000 compared to $13,000,000 in the prior year [28] Business Line Data and Key Metrics Changes - Clinical diagnostic business had its highest quarterly revenue to date, contributing to overall revenue growth [8] - Molecular tests delivered increased by 52% to 2,184 tests compared to 1,441 in Q4 2024 [10] - The company expects 30% to 40% quarter-over-quarter growth in molecular results for 2025 [9] Market Data and Key Metrics Changes - The MRD testing market is projected to mature into a $20,000,000,000 market, with Personalis positioned for success [6] - Approximately 40% of MRD positive results are in the ultra-sensitive range, which is a key differentiator [11] Company Strategy and Development Direction - The company is focused on a "win in MRD" strategy, emphasizing customer care and robust experience [12] - Plans to deepen clinical evidence and achieve reimbursement for three indications: breast cancer, lung cancer, and immunotherapy monitoring [12] - The company is targeting to achieve reimbursement for at least two indications in 2025 [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving revenue guidance of $80,000,000 to $90,000,000 for 2025, despite potential reimbursement timing variability [30] - The company is optimistic about the impact of its ultra-sensitive MRD tests on patient management and outcomes [22] Other Important Information - Cash and cash equivalents at the end of the quarter were $185,700,000, providing a comfortable runway for growth objectives [8] - The company raised approximately $17,800,000 through common stock sales during the quarter [29] Q&A Session Summary Question: Will the company steer its commercial organization towards breast cancer patients if reimbursement comes through this year? - Management confirmed that efforts are already focused on breast cancer, lung cancer, and immunotherapy monitoring, with plans to accelerate once reimbursement is clear [33][34] Question: What is the retention rate of doctors ordering tests? - Management reported high retention rates, with several hundred physicians ordering tests, a mix of new and recurring orders [36] Question: How does the company view the growth in marketing efforts pre- and post-reimbursement? - Management indicated that they are currently metering growth but can accelerate efforts significantly once reimbursement is achieved [40][41] Question: Can the company provide insights on the demographics of patients in the Victory study? - Management noted that the study included a cross-section of colorectal cancer patients across all stages, with high sensitivity in detecting recurrences [55] Question: What is the company's confidence level regarding reimbursement approval timelines? - Management expressed confidence in the process, stating that they have not seen any impact from changes in Washington on their timelines [92]

PART I — FINANCIAL INFORMATION [Financial Statements](index=7&type=section&id=Item%201.%20Financial%20Statements) This section presents the unaudited consolidated financial statements for Personalis, Inc. for the three months ended March 31, 2025, covering balance sheets, operations, and cash flows [Consolidated Balance Sheets](index=7&type=section&id=Consolidated%20Balance%20Sheets) As of March 31, 2025, total assets slightly increased to **$273,308 thousand**, with total liabilities decreasing and stockholders' equity rising Consolidated Balance Sheet Highlights (in thousands) | Balance Sheet Item | March 31, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $71,001 | $91,415 | | Short-term investments | $114,687 | $93,594 | | Total current assets | $206,422 | $203,015 | | Total assets | $273,308 | $270,268 | | **Liabilities & Stockholders' Equity** | | | | Total current liabilities | $29,892 | $31,126 | | Total liabilities | $65,963 | $67,311 | | Total stockholders' equity | $207,345 | $202,957 | [Consolidated Statements of Operations](index=8&type=section&id=Consolidated%20Statements%20of%20Operations) For Q1 2025, revenue increased 6% to **$20,605 thousand**, with net loss widening to **$15,750 thousand** due to a prior-year non-cash gain Q1 2025 vs Q1 2024 Statement of Operations (in thousands) | Metric | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Revenue | $20,605 | $19,525 | | Cost of revenue | $13,398 | $14,032 | | Loss from operations | $(17,696) | $(18,880) | | Other income (expense), net | $(46) | $4,569 | | Net loss | $(15,750) | $(12,968) | | Net loss per share | $(0.18) | $(0.26) | [Consolidated Statements of Cash Flows](index=11&type=section&id=Consolidated%20Statements%20of%20Cash%20Flows) In Q1 2025, net cash used in operating activities improved to **$17,961 thousand**, with financing activities providing **$20,087 thousand** Cash Flow Summary (in thousands) | Cash Flow Activity | Three Months Ended March 31, 2025 | Three Months Ended March 31, 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | $(17,961) | $(20,413) | | Net cash (used in) provided by investing activities | $(22,542) | $6,301 | | Net cash provided by financing activities | $20,087 | $1,129 | | Net change in cash, cash equivalents and restricted cash | $(20,414) | $(13,003) | [Notes to Consolidated Financial Statements](index=12&type=section&id=Notes%20to%20Consolidated%20Financial%20Statements) The notes detail accounting policies, revenue disaggregation, and balance sheet components, highlighting significant customer concentration - The company operates as one reportable segment, providing advanced cancer genomic tests and services, and expects to continue incurring losses[47](index=47&type=chunk)[48](index=48&type=chunk) Customer Concentration (Q1 2025) | Customer | Revenue % | Accounts Receivable % | | :--- | :--- | :--- | | Moderna, Inc. | 27% | 14% | | VA MVP | 20% | 11% | | Natera, Inc. | 12% | * | | Pfizer Inc. | * | 26% | | AstraZeneca UK Limited | * | 18% | *Less than 10% Revenue by Customer Type (in thousands) | Customer Type | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Pharma tests and services | $13,594 | $9,812 | | Enterprise sales | $2,465 | $7,972 | | Population sequencing | $4,213 | $1,500 | | Clinical diagnostic | $308 | $195 | | Other | $25 | $46 | | **Total revenue** | **$20,605** | **$19,525** | - In Q1 2025, the company sold **3,064,152 shares** under its At-the-Market (ATM) facility, receiving **$17,800 thousand** in net proceeds[56](index=56&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=29&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses Q1 2025 financial performance, highlighting a 6% revenue increase driven by Pharma tests and Population sequencing, and details liquidity [Results of Operations](index=32&type=section&id=Results%20of%20Operations) Total revenue for Q1 2025 increased 6% to **$20,605 thousand**, driven by Pharma tests and Population sequencing, partially offset by decreased Enterprise sales Revenue Change by Customer Type (Q1 2025 vs Q1 2024, in thousands) | Customer Type | 2025 | 2024 | Change | % Change | | :--- | :--- | :--- | :--- | :--- | | Pharma tests and services | $13,594 | $9,812 | $3,782 | 39% | | Enterprise sales | $2,465 | $7,972 | $(5,507) | (69%) | | Population sequencing | $4,213 | $1,500 | $2,713 | 181% | | Clinical diagnostic | $308 | $195 | $113 | 58% | | **Total revenue** | **$20,605** | **$19,525** | **$1,080** | **6%** | - The company expects total revenue from Natera in 2025 to be lower than in 2024 and does not expect a long-term commercial relationship beyond 2025[145](index=145&type=chunk) - The increase in Selling, general and administrative expenses was driven by an **$800 thousand** increase in marketing and personnel costs related to the NeXT Personal Dx launch[152](index=152&type=chunk)[153](index=153&type=chunk) - Other income in Q1 2024 included a **$4,800 thousand** non-cash gain from Tempus Warrants, contributing to the higher net loss in Q1 2025[156](index=156&type=chunk) [Liquidity and Capital Resources](index=35&type=section&id=Liquidity%20and%20Capital%20Resources) As of March 31, 2025, Personalis had **$185,700 thousand** in cash and investments, deemed sufficient for the next 12 months, with **$17,800 thousand** raised from ATM facility - The company anticipates that current cash, cash equivalents, and short-term investments are sufficient to fund operations for at least the next **12 months**[158](index=158&type=chunk) - Cash used in operating activities decreased to **$18,000 thousand** in Q1 2025 from **$20,400 thousand** in Q1 2024, due to higher gross margin and reduced working capital needs[161](index=161&type=chunk) - Cash provided by financing activities increased significantly to **$20,100 thousand** in Q1 2025, primarily due to **$16,300 thousand** higher net proceeds from ATM stock sales[163](index=163&type=chunk) - Capital expenditures are expected to be approximately **$8,000 thousand** in 2025 to expand NeXT Personal Dx capacity[167](index=167&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=37&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company is not required to provide this information as it qualifies as a "smaller reporting company" - As a "smaller reporting company," Personalis is not required to provide the information requested under this item[174](index=174&type=chunk) [Controls and Procedures](index=37&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that the company's disclosure controls and procedures were effective as of March 31, 2025, with no material changes in internal controls - The CEO and CFO concluded that as of March 31, 2025, the company's disclosure controls and procedures were effective[175](index=175&type=chunk) - No changes were identified in the company's internal control over financial reporting that materially affected or are reasonably likely to materially affect controls[176](index=176&type=chunk) PART II — OTHER INFORMATION [Legal Proceedings](index=38&type=section&id=Item%201.%20Legal%20Proceedings) The company states that it is subject to various claims in the ordinary course of business but is not currently involved in any material legal proceedings - As of March 31, 2025, the Company was not involved in any material legal proceedings[116](index=116&type=chunk)[179](index=179&type=chunk) [Risk Factors](index=38&type=section&id=Item%201A.%20Risk%20Factors) This section details significant risks, including a history of losses, customer concentration, intense competition, potential FDA regulatory actions, cybersecurity threats, and intellectual property litigation [Operational, Strategic and Business Risks](index=38&type=section&id=Operational%2C%20Strategic%20and%20Business%20Risks) The company faces significant operational and strategic risks, including a history of losses, substantial customer concentration, and reliance on a single facility and sole supplier - The company has a history of net losses, with a net loss of **$16,000 thousand** for Q1 2025 and an accumulated deficit of **$566,000 thousand** as of March 31, 2025[181](index=181&type=chunk) - The company has substantial customer concentration, with Natera accounting for **30%** of revenue and Moderna for **28%** in FY2024[191](index=191&type=chunk) - The company does not expect a long-term commercial relationship with Natera beyond 2025, as Natera plans to bring sequencing services in-house[193](index=193&type=chunk) - The company relies on a sole supplier, Illumina, for its sequencers and reagents, where supply disruption could significantly impact operations[208](index=208&type=chunk) [Regulatory, Legal and Cybersecurity Risks](index=61&type=section&id=Regulatory%2C%20Legal%20and%20Cybersecurity%20Risks) The company faces significant regulatory risks from potential FDA enforcement on LDTs, compliance with complex healthcare laws, cybersecurity threats, and evolving data privacy regulations - The company's LDTs are subject to FDA enforcement discretion, and a change in stance could lead to substantial costs and delays for premarket approval[249](index=249&type=chunk)[253](index=253&type=chunk) - The company's operations are subject to complex laws like the Anti-Kickback Statute, Stark Law, and HIPAA, with violations carrying significant penalties[301](index=301&type=chunk) - The company faces significant cybersecurity risks, including ransomware and supply-chain attacks, potentially compromising sensitive data and leading to litigation[273](index=273&type=chunk)[274](index=274&type=chunk)[275](index=275&type=chunk) - The company is subject to evolving U.S. and foreign data privacy laws (e.g., CCPA, GDPR), imposing strict obligations and risks of substantial fines[288](index=288&type=chunk)[289](index=289&type=chunk)[291](index=291&type=chunk) [Intellectual Property Risks](index=86&type=section&id=Intellectual%20Property%20Risks) The company's success depends on avoiding third-party patent infringement and protecting its own IP, facing risks of costly litigation and challenges in patent enforcement - The company faces a high risk of litigation for intellectual property infringement, which could be costly and prevent the sale of its tests[323](index=323&type=chunk)[325](index=325&type=chunk) - Recent legal proceedings include two of the company's patents being challenged and invalidated during inter partes reviews by Foresight Diagnostics[344](index=344&type=chunk)[345](index=345&type=chunk) - The company's ability to obtain and enforce patents is uncertain due to evolving case law regarding the patentability of diagnostic methods[333](index=333&type=chunk) - The company relies on trade secrets and confidentiality agreements, but these may not provide adequate protection, risking competitive harm[348](index=348&type=chunk) [Financial and Market Risks](index=100&type=section&id=Financial%20and%20Market%20Risks) The company faces financial and market risks, including the potential need for additional capital, stock price volatility, concentrated ownership, and potential stock dilution - The company may need to raise additional capital, which could be impacted by worsening global economic conditions and market volatility[364](index=364&type=chunk)[366](index=366&type=chunk) - The market price of the company's common stock is volatile, influenced by operating results, competition, and major customer announcements[367](index=367&type=chunk)[368](index=368&type=chunk) - Insiders and holders of over **5%** of common stock may exercise significant control, potentially influencing corporate matters and stock price[379](index=379&type=chunk) - The company's ability to use its net operating loss carryforwards of approximately **$324,100 thousand** (federal) and **$302,500 thousand** (state) may be limited by ownership changes[386](index=386&type=chunk) [Other Information](index=114&type=section&id=Item%205.%20Other%20Information) This section discloses that an officer of the company adopted a written trading plan under Rule 10b5-1 during the last fiscal quarter - Stephen Moore, SVP and Chief Legal Officer, adopted a Rule 10b5-1 trading plan on March 24, 2025, to sell up to **285,366 shares** of common stock[409](index=409&type=chunk) [Exhibits](index=115&type=section&id=Item%206.%20Exhibits) This section lists the exhibits filed with the Quarterly Report on Form 10-Q, including certifications by the Principal Executive Officer and Principal Financial Officer, and the Inline XBRL documents - The exhibits include the CEO and CFO certifications pursuant to Sarbanes-Oxley Act Sections 302 and 906, and Inline XBRL data for financial statements[413](index=413&type=chunk)

[Personalis Q1 2025 Earnings Release](index=1&type=section&id=Personalis%20Q1%202025%20Earnings%20Release) [Financial & Business Highlights](index=1&type=section&id=Recent%20Business%20Highlights) Personalis reported a strong start to 2025, with total revenue increasing 6% year-over-year to $20.6 million, driven by a 39% growth in pharma tests and services - The company's "Win-in-MRD" strategy is showing positive results, with significant growth in testing volume and key data submissions for Medicare coverage[3](index=3&type=chunk) Clinical Test Volume Growth (Sequential) | Metric | Q1 2025 | Q4 2024 | Change | | :--- | :--- | :--- | :--- | | Total Molecular Tests Delivered | 2,184 | 1,441 | +52% | - Presented compelling clinical data for NeXT Personal in colorectal cancer (CRC) at AACR, showing **100% detection of eventual recurrence prior to imaging**[4](index=4&type=chunk) - Advanced its commercialization efforts by publishing a pivotal breast cancer study and submitting a dossier to Medicare for reimbursement[4](index=4&type=chunk) [Detailed Financial Results (Q1 2025 vs Q1 2024)](index=1&type=section&id=First%20Quarter%202025%20Financial%20Results%20Compared%20with%202024) For Q1 2025, total revenue grew 6% to $20.6 million, primarily fueled by a 39% increase in pharma tests and services, which reached $13.6 million Q1 2025 Key Financial Metrics vs. Q1 2024 | Metric | Q1 2025 | Q1 2024 | Change | | :--- | :--- | :--- | :--- | | Total Revenue | $20.6M | $19.5M | +6% | | Gross Margin | 35.0% | 28.1% | +6.9 p.p. | | Net Loss | $15.8M | $13.0M | +21.5% | | Net Loss Per Share | ($0.18) | ($0.26) | N/A | Q1 2025 Revenue Breakdown vs. Q1 2024 | Revenue Segment | Q1 2025 | Q1 2024 | Change | | :--- | :--- | :--- | :--- | | Pharma tests and services | $13.6M | $9.8M | +39% | | Population sequencing & enterprise | $6.7M | $9.5M | -29% | - The company ended the quarter with **$185.7 million in cash, cash equivalents, and short-term investments**; cash usage from operations and capital additions was **$20.5 million**[6](index=6&type=chunk) - Raised **$17.8 million in net proceeds** during the quarter through its At-The-Market (ATM) program[6](index=6&type=chunk) [Financial Outlook (Q2 & Full Year 2025)](index=2&type=section&id=Second%20Quarter%20and%20Full%20Year%202025%20Outlook) Personalis provided guidance for Q2 2025, expecting total revenue between $19.5 million and $20.5 million, and updated its full-year outlook to reflect improved profitability Q2 2025 Financial Guidance | Metric | Guidance Range | | :--- | :--- | | Total Company Revenue | $19.5M - $20.5M | | Revenue from Pharma & Other | $13.0M - $14.0M | | Revenue from Pop Sequencing & Enterprise | ~$6.5M | Full Year 2025 Financial Guidance (Updated) | Metric | Guidance Range | Prior Guidance | | :--- | :--- | :--- | | Total Company Revenue | $80M - $90M | No Change | | Gross Margin | 22% - 24% | 21% - 23% | | Net Loss | ~$83M | ~$85M | | Cash Usage | ~$75M | $75M - $80M | [Financial Statements](index=4&type=section&id=Financial%20Statements) This section presents the company's consolidated financial statements, including statements of operations, supplemental revenue information, and balance sheets [Consolidated Statements of Operations](index=4&type=section&id=CONSOLIDATED%20STATEMENTS%20OF%20OPERATIONS%20(Unaudited)) For the three months ended March 31, 2025, Personalis recorded revenues of $20.6 million and a net loss of $15.8 million, with a slight improvement in loss from operations Consolidated Statements of Operations (Unaudited, In thousands) | | Three Months Ended March 31, | | :--- | :--- | :--- | | | **2025** | **2024** | | **Revenue** | **$ 20,605** | **$ 19,525** | | Cost of revenue | 13,398 | 14,032 | | Research and development | 12,640 | 12,771 | | Selling, general and administrative | 12,263 | 11,602 | | **Total costs and expenses** | **38,301** | **38,405** | | **Loss from operations** | **(17,696)** | **(18,880)** | | Interest income | 2,027 | 1,359 | | Other income (expense), net | (46) | 4,569 | | **Net loss** | **$ (15,750)** | **$ (12,968)** | [Supplemental Revenue Information](index=5&type=section&id=SUPPLEMENTAL%20REVENUE%20INFORMATION%20(Unaudited)) Revenue from pharma tests and services was the primary growth driver, increasing 39% to $13.6 million, while enterprise sales significantly decreased Supplemental Revenue Information (Unaudited, In thousands) | | Three Months Ended March 31, | | :--- | :--- | :--- | | | **2025** | **2024** | | Pharma tests and services | $ 13,594 | $ 9,812 | | Enterprise sales | 2,465 | 7,972 | | Population sequencing | 4,213 | 1,500 | | Clinical diagnostic | 308 | 195 | | Other | 25 | 46 | | **Total revenue** | **$ 20,605** | **$ 19,525** | [Consolidated Balance Sheets](index=6&type=section&id=CONSOLIDATED%20BALANCE%20SHEETS%20(Unaudited)) As of March 31, 2025, Personalis maintained strong liquidity with $185.7 million in cash and investments, and total assets of $273.3 million Consolidated Balance Sheet Highlights (Unaudited, In thousands) | | March 31, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $ 71,001 | $ 91,415 | | Short-term investments | 114,687 | 93,594 | | **Total current assets** | **206,422** | **203,015** | | **Total assets** | **$ 273,308** | **$ 270,268** | | **Liabilities and Stockholders' Equity** | | | | Total current liabilities | 29,892 | 31,126 | | **Total liabilities** | **65,963** | **67,311** | | **Total stockholders' equity** | **207,345** | **202,957** | | **Total liabilities and stockholders' equity** | **$ 273,308** | **$ 270,268** |

The Hanover Insurance Group (THG) is expected to register an improvement in its top and bottom lines when it reports first-quarter 2025 results on April 30, after the closing bell.The Zacks Consensus Estimate for THG’s first-quarter revenues is pegged at $1.7 billion, indicating a 6.5% increase from the year-ago reported figure. The consensus estimate for the bottom line is pegged at $3.58 per share. The estimate suggests a year-over-year increase of 144.4%. The Zacks Consensus Estimate for THG’s first-quar ...

Personalis, Inc. (NASDAQ:PSNL) Q4 2024 Earnings Conference Call February 27, 2025 5:00 PM ET Company Participants Caroline Corner - Investor Relations Christopher Hall - Chief Executive Officer and President Aaron Tachibana - Chief Financial and Chief Operating Officer Richard Chen - Executive Vice President, R&D, and Chief Medical Officer Conference Call Participants Thomas Flaten - Lake Street Swayampakula Ramakanth - H.C. Wainwright William Ruby - TD Cowen Operator Ladies and gentlemen, greetings and wel ...

Company Performance - Personalis reported a quarterly loss of $0.23 per share, better than the Zacks Consensus Estimate of a loss of $0.25, and an improvement from a loss of $0.46 per share a year ago, representing an earnings surprise of 8% [1] - The company posted revenues of $16.8 million for the quarter ended December 2024, slightly surpassing the Zacks Consensus Estimate by 0.06%, but down from $19.68 million in the same quarter last year [2] - Over the last four quarters, Personalis has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] Stock Outlook - Personalis shares have declined approximately 22.5% since the beginning of the year, contrasting with the S&P 500's gain of 1.3% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.26 on revenues of $15.22 million, and for the current fiscal year, it is -$0.99 on revenues of $85.13 million [7] - The estimate revisions trend for Personalis is currently unfavorable, resulting in a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [6] Industry Context - The Medical - Generic Drugs industry, to which Personalis belongs, is currently ranked in the bottom 22% of over 250 Zacks industries, suggesting a challenging environment [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Personalis's stock performance [5]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______. Commission File Number 001-38943 Personalis, Inc. (Exact name of Registrant as specified in its Charter) Delaware 27-5411038 (State or other jurisdiction ...

Wall Street expects a year-over-year increase in earnings on lower revenues when Personalis (PSNL) reports results for the quarter ended December 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on February 27. ...